MedTrace Logo

An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder

NCT01038128 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-05-04

Study results available
· View outcomes & findings →

Summary

The primary objective of this 13-week clinical trial is to test the hypothesis that treatment with Memantine will significantly improve the symptoms of those suffering from either bulimia nervosa, purging type or suffering from body dysmorphic disorder.

Conditions

  • Bulimia Nervosa
  • Body Dysmorphic Disorder

Interventions

DRUG

Memantine

Drug: Memantine, 10-40 mg daily

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • James I Hudson, M.D., Sc.D. · Mclean Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038128 on ClinicalTrials.gov